Molecular Mechanisms Reducing Predisposed Risk to Breast Cancer (Synergy)

Submitted by Anelia Horvath, PhD, Rebecca Kaltman, MD, and Christine Teal, MD
April 28, 2014


This proposal aims to define the genetic and expression background accompanying BRCA1 and BRCA2 pathogenic mutations in individuals who have not developed an early onset cancer, in comparison with mutation carriers with an early onset disease. To establish: (1) genome-scale analytical platform for comparative genomic mining of BRCA1/2 mutation carriers with and without an early onset breast cancer; (2) bio-bank for intra-familial wet-lab comparative studies on BRCA1/2 positive individuals.

Submitted By:

Anelia Horvath, Ph.D.

Rebecca Kaltman, M.D.

Christine Teal, M.D.